{"DataElement":{"publicId":"7421801","version":"1","preferredName":"Letermovir Primary Prophylaxix Start Date","preferredDefinition":"Start date of Letermovir primary prophylaxis.","longName":"LTRMV_PR_PROX_ST_DT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"7421723","version":"1","preferredName":"Letermovir Primary Preventive Intervention Begin","preferredDefinition":"An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented._Occurring first in time or sequence; original; of greatest rank or importance or value._Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","longName":"7421714v1.0:7421721v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"7421714","version":"1","preferredName":"Letermovir","preferredDefinition":"An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.","longName":"C115099","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letermovir","conceptCode":"C115099","definition":"An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF5EBFA5-4ACD-5327-E053-4EBD850A2AF4","latestVersionIndicator":"Yes","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7421721","version":"1","preferredName":"Primary Preventive Intervention Begin","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.:In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet).:Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","longName":"C25251:C15843:C25431","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Begin","conceptCode":"C25431","definition":"Have a beginning, in a temporal, spatial, or evaluative sense; the point in space or time where something begins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF5F00F1-C7A4-030D-E053-4EBD850A7800","latestVersionIndicator":"Yes","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"ONEDATA","dateModified":"2020-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF5F00F1-C7B5-030D-E053-4EBD850A7800","latestVersionIndicator":"Yes","beginDate":"2020-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-15","modifiedBy":"HARTLEYG","dateModified":"2020-10-02","changeDescription":"Created for NCI-INC0519249 - BK and CMV qns curation 9.11.20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017121","version":"1","preferredName":"CTMS Date","preferredDefinition":"Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"CTMS_DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"4","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"DD/MON/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"A6545B3B-0FC3-40BF-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-21","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-21","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/30/17 jk Transferred context, added CSI and reg status, released per Round 5 finalization task. --- Display and exchange formats are based on CTMS reporting requirements v.3.02 and all subsequent versions of these guidelines.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Letermovir primary prophylaxi","type":"Preferred Question Text","description":"Letermovir primary prophylaxis start date","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF6F6001-D95A-186A-E053-4EBD850A1B07","latestVersionIndicator":"Yes","beginDate":"2020-09-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-09-16","modifiedBy":"HARTLEYG","dateModified":"2020-10-02","changeDescription":"Created for NCI-INC0519249 - BK and CMV qns curation 9.11.20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}